Your browser doesn't support javascript.
loading
Aspirin administration from early pregnancy versus initiation after 11 weeks of gestation for prevention of pre-eclampsia in high-risk pregnant women: Study protocol for randomized controlled trial.
Hantoushzadeh, Sedigheh; Behzadian, Arezoo; Mehdi Hasheminejad, Mohammad; Hasheminejad, Faezeh; Helal Birjandi, Alireza; Akbari, Mojtaba; Ghaemi, Marjan.
Afiliación
  • Hantoushzadeh S; Vali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
  • Behzadian A; Department of Perinatology, Vali-E-Asr Hospital, Imam Khomeini Hospital Complex, Tehran, Iran.
  • Mehdi Hasheminejad M; Iran University of Medical Sciences, Tehran, Iran.
  • Hasheminejad F; Asklepios Psychiatry Lower Saxony GmbH, Asklepios Specialist Clinic, Gottingen, Germany.
  • Helal Birjandi A; Hannover Medical School, Clinic for Urology, Hannover, Germany.
  • Akbari M; Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medicine Sciences, Isfahan, Iran.
  • Ghaemi M; Vali-E-Asr Hospital, Imam Khomeini Hospital Complex, Iran.
Int J Reprod Biomed ; 22(1): 69-80, 2024 Jan.
Article en En | MEDLINE | ID: mdl-38544665
ABSTRACT

Background:

Pre-eclampsia (PE) is a multiorgan disorder that affects 2-5% of all pregnant women. Present recommendations for when to start aspirin in high-risk women are after 11 wk of gestation.

Objective:

We present a protocol to investigate the effectiveness of aspirin use from early pregnancy, which is a randomized controlled trial to assess whether prescribed low-dose aspirin from early pregnancy reduces the prevalence of early and late-onset PE. Additionally, to compare the effectiveness of aspirin administration before and after 11 wk in reducing the occurrence of PE? Materials and

Methods:

All pregnancies at risk of PE, according to demographic and midwifery history, who are referred to the Maternal-Fetal Clinic of Tehran University hospital, Tehran, Iran were invited to take part in the trial. The outcomes of pregnancy and newborns will be gathered and analyzed. The first registration for the pilot study was in January 2023, and the participants were recognized as high-risk for PE. In addition, enrollment in the main study will begin as of October 2023.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Reprod Biomed Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Irán
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Reprod Biomed Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Irán